You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 246 No. 15, October 9, 1981 TABLE OF CONTENTS
  JAMA
  •  Online Features
  CLINICAL NOTES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Fatal Vidarabine Toxicity in a Patient With Normal Renal Function

Linda Van Etta, MD; John Brown, MD; Angeline Mastri, MD; Thomas Wilson, MD

JAMA. 1981;246(15):1703-1705.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

PATIENTS experiencing disseminated varicella-zoster infection may have significant morbidity in the form of pain, extreme fevers (temperature ≥40 °C), rigors, anorexia, malaise, and, rarely, pneumonia, hepatitis, and encephalitis.1 Initially, vidarabine sodium phosphate showed promising results in disseminated herpes zoster with a very low incidence of clinical toxicity.2 More recently, however, several authors have reported cases of possible neurological toxicity. This toxicity was manifested by tremors, dysarthria, confusion, coma, or a combination.3-5 Death occurred in several patients.6 Except for one patient with evidence of renal insufficiency, symptoms developed during administration of the drug.

We have recently observed a patient with disseminated varicella-zoster infection in whom severe, ultimately fatal, CNS symptoms developed 48 hours after completion of an initial three-day course of vidarabine. We report the details of this case of apparent vidarabine CNS toxicity that occurred in the presence of normal renal function in a patient with . . . [Full Text PDF of this Article]


Author Affiliations

From the Infectious Disease Section, Medical Service, Veterans Administration Medical Center (Dr Van Etta); the Department of Neuropathology, University of Minnesota Medical School (Dr Mastri); and the Departments of Medical Oncology and Neurology (Drs Brown and Wilson), Abbott-Northwestern Hospital, Minneapolis.


Footnotes

Reprint requests to the Infectious Disease Section, Veterans Administration Medical Center, 54th Street and 48th Avenue S, Minneapolis, MN 55417 (Dr Van Etta).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1981 American Medical Association. All Rights Reserved.